Association between plasminogen activator inhibitor-1 -675 4G/5G polymorphism and sepsis: a meta-analysis

PLoS One. 2013;8(1):e54883. doi: 10.1371/journal.pone.0054883. Epub 2013 Jan 30.

Abstract

Background: Several studies have evaluated the association between plasminogen activator inhibitor-1 (PAI-1) -675 4G/5G polymorphism and sepsis in different populations. However, the available results are conflicting.

Methods: A search of Pubmed and EMBASE databases was performed to identify relevant studies for inclusion in the meta-analysis. Odds ratios (ORs) and corresponding 95% confidence intervals (CIs) were determined using a random-effects model.

Results: Twelve case-control studies and three cohort studies were included. Overall, a significant association between 4G/5G polymorphism and sepsis risk was observed for 4G/4G vs. 4G/5G +5G/5G (OR = 1.30, 95% CI 1.08-1.56, P = 0.006). In addition, there was a significant association between PAI-1 4G/5G polymorphism and sepsis-related mortality (OR = 1.72, 95% CI 1.27-2.33, P = 0.0005). In subgroup analyses, increased sepsis risk and mortality risk were found in Caucasians and in patients with sepsis.

Conclusions: This meta-analysis suggested that the PAI-1 -675 4G/5G polymorphism was a risk factor for sepsis and sepsis mortality.

Publication types

  • Meta-Analysis
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Genetic Association Studies
  • Humans
  • Odds Ratio
  • Plasminogen Activator Inhibitor 1 / genetics*
  • Polymorphism, Single Nucleotide*
  • Publication Bias
  • Risk
  • Sepsis / genetics*
  • Sepsis / mortality

Substances

  • Plasminogen Activator Inhibitor 1

Grants and funding

This study was supported by National Natural Science Foundation of China (NO. 81070003) and Natural Science Foundation of Guangdong province (NO. 10151001002000005). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.